Unlocking the power of allogeneic T-cell therapies to fight cancer and infection

Smart Immune is a clinical-stage biotechnology company developing ProTcell™a thymus-empowered cell therapy platform to fully and rapidly re-arm the immune system, enabling next generation allogeneic T-cell therapies for all.

A groundbreaking technology

The ProTcell™platform

Through its patented and proprietary ex vivo lymphoid technology, Smart Immune has developed a T-cell progenitor-based cell therapy platform, called the ProTcell™ platform. It has been designed to enable rapid and full re-arming of the immune system, so patients can fight life-threatening disorders. Our lymphoid progenitors have a remarkable dual potential of differentiation:  
- T lineage: when directly infused to patients, they complete their differentiation into the thymus recipient to become polyclonal and fully efficient T cells.
- NK lineage: when further cultured ex vivo through a dedicated process they can differentiate into early NK effectors.

For the first time in human medicine, Smart Immune is enabling access to long-lasting, allogeneic T-cell progenitors, minimising donor matching requirements and accelerating full immune recovery.